One hundred years ago dementing illnesses were classified based upon their clinical presentation and neuropathology. T he promise of the twenty first century is that w e w ill be able to classify these same diseases by t he genetic cause or genetic risk factors, a classification based upon etiology not symptomatology. During the last two decades mutations in many genes have been shown to cause Inherited forms of early onset dementing illnesses. These rare disorders have provided enormous insight into the pathogenesis of more common variants of the same diseases. A growing realization of the importance of genetic risk factors for common diseases has led the research community to assess the role of genetic as well as environmental risk factors in susceptibility for late onset Alzheimer's disease. In 1993, polymorphism in t he apolipoprotein E (APOE) gene w as shown to be the first identified risk factor for AD. A dose-dependent effect o f t he AP0E4 allele has been observed in al most every population studied. APOE genotype has now become an important variable in clinical and pathological studies of AD. Indeed, all clinical trials now evaluate putative AD drugs in AP0E4 positive and AP0E4 negative patient subgroups. The goal of the Genetics Core of the Washington University ADRC is to provide genetic information and useful materials on all ADRC participants. In the case of late onset AD we will obtain family history data, APOE genotypes and bank plasma and serum samples. This data will be stored in the master ADRC database and provided to investigators upon request and thus specifically will support Projects 1 (Perrin) and 3 (Bateman) of this competing renewal application. When new genetic risk factors are identified we will also provide this information where possible. In the case of multiplex kindreds we will collect family history data and screen individuals for mutations in the known dementia causing genes. Cell lines and brains from these individuals will be available for molecular studies on the effects of specific mutations.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148
Wildburger, Norelle C; Esparza, Thomas J; LeDuc, Richard D et al. (2017) Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. Sci Rep 7:9520
Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528
Roe, Catherine M; Babulal, Ganesh M; Head, Denise M et al. (2017) Preclinical Alzheimer's disease and longitudinal driving decline. Alzheimers Dement (N Y) 3:74-82
Neu, Scott C; Pa, Judy; Kukull, Walter et al. (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74:1178-1189
Miller-Thomas, Michelle M; Benzinger, Tammie L S (2017) Neurologic Applications of PET/MR Imaging. Magn Reson Imaging Clin N Am 25:297-313
Alosco, Michael L; Duskin, Jonathan; Besser, Lilah M et al. (2017) Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. J Alzheimers Dis 57:953-968
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2017) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord 31:69-72
Pandya, Seema Y; Lacritz, Laura H; Weiner, Myron F et al. (2017) Predictors of Reversion from Mild Cognitive Impairment to Normal Cognition. Dement Geriatr Cogn Disord 43:204-214
Lewczuk, Piotr; Matzen, Anja; Blennow, Kaj et al. (2017) Cerebrospinal Fluid A?42/40 Corresponds Better than A?42 to Amyloid PET in Alzheimer's Disease. J Alzheimers Dis 55:813-822

Showing the most recent 10 out of 825 publications